2026 Interim Report
Filed with HKEX · Stock code 7666 · · 125 pages · English
Dr. Tsai-Ta Lai (Chairman and chief executive officer) Dr. Hongming Chen Dr. Wenshou Wang Non-executive Directors Mr. Hantao Huang Ms. Yuan Gong Independent Non-executive Directors Mr. Frank Yee Chon Lyn Dr. Jin Li Dr. Peter Edward Lobie AUTHORIZED REPRESENTATIVES Dr. Tsai-Ta Lai Ms. Hei Chan (Appointed on June 12, 2026) Ms. Cheng Yuk Ting (Resigned on June 12, 2026) AUDIT COMMITTEE Mr. Frank Yee
Metis TechBio Co., Ltd. on 6ix
Earlier from Metis TechBio
- METiS TechBio and Boulevard Bio Enter Global License Agreement for Trispecific T-cell Engager
- METiS TechBio to Present Late-Breaking Data on Near-Complete Cardiomyocyte Delivery at CRS 2026
Later from Metis TechBio
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement Metis TechBio entered strategic collaboration with lilly to advance next-generation tissue-specific LNP delivery technologies
Follow Metis TechBio into a list and get an email when it puts out news.
Follow Metis TechBio